Fortrea Holdings Inc

FTRE

Equity

ISIN null / Valor 127734378

NASDAQ (2025-10-17)

USD 9.45-0.74%

Fortrea Holdings Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Fortrea Holdings Inc. operates as a global provider in the healthcare sector, specializing in a wide range of services that support the lifecycle of clinical trials from Phase I through IV. The company's offerings encompass clinical pharmacology, patient access solutions, and other essential services aimed at facilitating the development and delivery of healthcare innovations. Fortrea distinguishes itself by partnering with both emerging and established biopharmaceutical, as well as medical device and diagnostic companies, leveraging its expertise to advance healthcare solutions worldwide. With a workforce of over 19,000 professionals, Fortrea is committed to delivering customized clinical trial solutions through three primary delivery models: full service, functional service provision, or a hybrid approach. This tailored strategy enables the company to meet the diverse needs of its clients across nearly 100 countries, underscoring its role as a key player in driving global healthcare innovation.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Fortrea Holdings Inc achieved revenues of $710.3 million in the second quarter of 2025, up from $662.4 million in the same quarter last year, reflecting strong market demand and business expansion.

Net Loss and Goodwill Impairment

The company reported a GAAP net loss of $374.9 million, including a non-cash goodwill impairment charge of $309.1 million. This resulted in a diluted loss per share of $(4.14), compared to a loss of $(1.11) per share in Q2 2024.

Adjusted EBITDA

Fortrea Holdings Inc reported an adjusted EBITDA of $54.9 million for the second quarter of 2025, slightly decreasing from $55.2 million in the second quarter of 2024, highlighting stable operational performance.

Book-to-Bill Ratio and Backlog

The company maintained a backlog of $7,547 million with a book-to-bill ratio of 0.79x for the quarter, contributing to a trailing 12-month book-to-bill ratio of 1.10x, indicating steady future revenue streams.

Full-Year Guidance

Fortrea Holdings Inc raised its 2025 revenue guidance to a range of $2,600 million to $2,700 million and affirmed its adjusted EBITDA guidance, reflecting confidence in continued growth and operational efficiency.

Summarized from source with an LLMView Source

Key figures

-51.3%1Y

%3Y

%5Y

Performance

93.0%1Y

72.1%3Y

72.1%5Y

Volatility